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In primary Sjögren’s syndrome high absolute
numbers and proportions of B cells in parotid
glands predict responsiveness to rituximab as
deﬁned by ESSDAI, but not by SSRI
With great interest we have read the letter to the editor by
Cornec et al1 regarding our paper ‘Towards personalised treat-
ment in primary Sjögren’s syndrome (pSS): baseline parotid
histopathology predicts responsiveness to rituximab treatment’.2
In essence, we showed in our paper that absolute numbers of
CD20+ cells/mm2 of parenchyma of parotid gland tissue are
predictive for the responsiveness of patients with pSS to rituxi-
mab (RTX) treatment. Cornec et al argue that there is a discrep-
ancy in outcomes presented in their study and our study,1 as
they observed that a high proportion of minor salivary gland B
cells predict the absence of a clinical response to RTX.3 As we
will show and explain here, there is no inconsistency between
the two studies and most of the apparent discrepancy is likely
the result of differences in how the tissues are analysed and how
the disease activity is established.
ABSOLUTE NUMBERS VERSUS PROPORTIONS OF B CELLS
AND TECHNIQUE APPLIED
A major difference in the two studies is how B cells are assessed
in tissue sections of salivary gland biopsies of patients with pSS
before (and after) RTX treatment. We measured absolute
numbers of CD20+ B cells/mm2 of parenchyma, while Cornec
et al assessed the proportion of B cells.1 3 Obviously, even when
there is a change in absolute numbers of B cells in the tissue, the
B/T cell ratio still can remain the same. Thus, although higher
numbers of B cells, do not need to be reﬂected per se in higher
proportions of B cells, we also found in our study that patients
with higher absolute numbers of B cells in the glandular tissue,
had a higher B/B+T cell ratio. Furthermore, responders to RTX,
as deﬁned by a decrease in European League Against
Rheumatism (EULAR) Sjögren’s Syndrome Disease Activity
Index (ESSDAI) score of ≥3 (ΔESSDAI≥3) at 12 weeks after
treatment compared with baseline,4 had a higher B/B+T cell
ratio compared with non-responders (ﬁgure 1).
Nevertheless, there are some technical differences between the
two studies that warrant some attention. We counted the absolute
number of cells with HistoQuest software (V.3.5.3.0171,
Tissuegnostics, Vienna, Austria), a well known and widely used
image analysis software package within pathology. Since parotid
gland biopsies include areas of fat and ﬁbrous tissue and intrapar-
enchymal lymph nodes, we excluded these areas manually from
the analysis, in order to increase the accuracy of the data. We
would like to emphasise that, as stated in the section on
‘Immunohistochemical analysis’ in the materials and methods of
our article,2 the whole slide (except from fat and ﬁbrous tissue)
was evaluated and areas of interest were not electively chosen, as
implied by Cornec et al.1 The methodology used by Cornec et al
is based on digital pixel counting procedure developed by Costa
et al.1 3 5 We have some concerns about this method. First, with
the method of Costa et al extraglandular areas are not excluded
from the tissue specimen studied,5 which has the risk to include
in the counting inﬁltrating cells located in areas of non-interest,
for example, intraparenchymal fat tissue, ﬁbrous tissue and peri-
neural tissue. Second, although the number of pixels is reported
to correlate to the manually counted cells,5 the exact number of
pixels corresponding to one cell remains unknown. Moreover,
although the B-cell proportions assessed with the method of
Costa et al correlate moderately to focus scores,5 the focus score
does not give an indication about the severity of inﬂammation, as
discussed in our paper.2 As a consequence, when the area
covered by a single focus at baseline is rather large, a clinically
relevant decrease in the inﬂamed area is not necessary reﬂected
by a decrease in focus score. Apparently, the HistoQuest method
of counting the absolute number of cells is more precise in these
aspects. Thus, it would be interesting to know whether the
results reported by Cornec et al change if biopsies would have
been analysed with the HistoQuest software approach.3
ESSDAI VERSUS SJÖGREN’S SYNDROME RESPONSE INDEX
Another factor that contributes signiﬁcantly to the apparent
difference between the two studies concerns the way disease
activity has been deﬁned. Cornec et al pose that the discrepancy
in outcomes can partially be attributed to ineffectiveness of RTX
in improving systemic involvement as measured by ESSDAI.1
This prompted them to develop and use the Sjögren’s Syndrome
Response Index (SSRI), an index reﬂecting mainly the objective
and subjective sicca symptoms.6 When we applied the SSRI to
classify patients as responder or non-responder, we were unable
to detect any difference in our data in baseline CD20+ B-cells/
Figure 1 Proportions of baseline CD20+ cells in clinical responders
(n=11) and non-responders (n=5) as deﬁned by European League
Against Rheumatism Sjögren’s Syndrome Disease Activity Index
(ESSDAI), p<0.05. Horizontal lines indicate median values.
Figure 2 Numbers of baseline CD20+ cells/mm2 in clinical responders
(n=8) and non-responders (n=6) as deﬁned by Sjögren’s Syndrome
Response Index (SSRI). Horizontal lines indicate median values, ns:
non-signiﬁcant.
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mm2 parenchyma between responders and non-responders
(ﬁgure 2). Importantly, the agreement between ESSDAI and SSRI
in deﬁning responders in our study was rather poor (κ=0.25,
percentage of agreement 64%; data not shown). Based on these
ﬁndings we conclude that it is evident that ESSDAI and SSRI
measure different outcomes; the ESSDAI focuses on systemic
disease activity and the SSRI mainly on sicca-related complaints.
In this respect, it is also worth mentioning that in our placebo
treated patients, SSRI characterised 40% of the patients as
responders, while ESSDAI only 11%. ESSDAI has been proven
to be sensitive to measure the change in disease activity after
therapeutic interventions and also showed that RTX was effective
in our double-blind placebo-controlled RTX trial.4 7–10 Thus,
further validation is necessary for the SSRI.
DIFFERENCES IN GENERAL FEATURES
In addition to these two main aspects that result in the apparent
discrepancies between the two studies, there are also some other
differences that may inﬂuence differences in outcomes.
Baseline ESSDAI: although the baseline ESSDAI scores were
rather similar between the two studies (eight in our study and
10 in the TEARS study) only in our study the ESSDAI was pro-
spectively evaluated.11 12 In the TEARS study, the ESSDAI was
retrospectively evaluated.
Baseline salivary gland positivity: another major difference
between the two studies is the positivity of salivary gland biopsy
of the included patients; all patients in our study had a positive
parotid gland biopsy at baseline, while only 64% of the patients
included in the study by Cornec et al had a positive minor saliv-
ary gland biopsy.1 When excluding patients with a negative
minor salivary gland biopsy from the study by Cornec et al, the
median proportion of B cells in responders would have been
probably higher than in non-responders, which is in agreement
with the conclusion of our study.
Parotid versus minor salivary gland biopsy: the different histo-
pathological characteristics observed in parotid and minor salivary
gland biopsies complicate the comparison as, for example, the B/
T-cell ratio differs greatly. Minor salivary glands of healthy con-
trols may have a physiological inﬁltrate that consists mainly of
T-lymphocytes (and plasma cells), while parotid salivary gland
tissue of healthy controls shows rarely a lymphocytic inﬁltrate.
Although those differences have been shown by Pijpe et al,13 there
is still a need for larger studies focusing on the inherent differences
in the histopathological characteristics of parotid and minor saliv-
ary gland tissue in both patients with pSS and healthy controls.
SALIVARY GLAND ULTRASOUND
Like Cornec et al, we also feel that ultrasound has merit in the
diagnosis and assessment of the disease activity of pSS.1 14 15
However, before making salivary gland ultrasound a standard in
pSS diagnostics, disease monitoring and treatment evaluation,
there are several questions that need to be answered ﬁrst, that is,
the reliability of ultrasound in the evaluation of changes that
occur in the major salivary glands of patients with pSS, and the
validity of ultrasound to detect the histopathological changes
occurring in the parotid tissue of patients (suspected) with pSS
(in particular direct comparison of ultrasonographical and histo-
pathological features).
From the above-mentioned, it may be concluded that our study
and the study of Cornec et al differ in some respect,2 3 but do not
present contradicting results. Most likely differences in assessment
of patients’ responsiveness to RTX treatment by using different
methods and techniques lead to different results and apparent dif-
ferences (table 1). Probably, by combining theirs and our analyses
we might even be able to more efﬁciently select patients at baseline
who probably will beneﬁt from RTX treatment.
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Table 1 Comparison of two studies
Study Cornec et al3 Delli et al2
Outcome Proportion of B cells Absolute number of CD20+B-cells/mm2 parenchyma
Software Digital pixel counting software, developed by the same team5 HistoQuest software, V.3.5.3.0171, Tissuegnostics, Vienna, Austria
Tool for measuring response to RTX SSRI6 ESSDAI4
Salivary gland Minor salivary glands Parotid gland
General features ▸ Baseline ESSDAI:10
▸ Median age: 50.4 and 54.8 (±9.5 and ±13.8)
▸ Baseline salivary gland biopsy positivity: 64%
▸ Baseline anti-SSA positivity: 80%
▸ Baseline ESSDAI: 8
▸ Median age: 43 (±11 years)
▸ Baseline salivary gland biopsy positivity: 100%
▸ Baseline anti-SSA positivity: 100%
ESSDAI, European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index; RTX, rituximab; SSRI, Sjögren’s Syndrome Response Index.
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